Company news

Pharvaris N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

June 3, 2024

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 12, 2024

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 9, 2024

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

April 9, 2024

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

April 3, 2024

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

March 17, 2024

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

March 5, 2024

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

March 4, 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 21, 2024

Pharvaris Announces Extraordinary Meeting of Shareholders

February 15, 2024

Pharvaris to Present at the WSAAI Annual Meeting 2024

January 25, 2024

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

January 21, 2024

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

January 4, 2024

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

December 7, 2023

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

December 5, 2023

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

December 5, 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

November 29, 2023

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

November 14, 2023

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

November 8, 2023

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

October 29, 2023

Pharvaris To Present at the APAAACI 2023 International Conference

October 12, 2023

Pharvaris To Present at the CIIC Fall 2023 Conference

October 3, 2023

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

September 18, 2023

Pharvaris To Present at the 18th German Allergy Congress

September 5, 2023

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 5, 2023

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

August 22, 2023

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

July 20, 2023

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

June 25, 2023

Pharvaris Announces $70 Million Private Placement Financing

June 19, 2023

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

June 10, 2023

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

May 5, 2023

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

April 4, 2023

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

March 17, 2023

Pharvaris to Present in Upcoming March Investor Conferences

March 1, 2023

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

February 23, 2023

Pharvaris to Present at SVB Securities Global Biopharma Conference

February 7, 2023

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

January 8, 2023

Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update

December 7, 2022

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

December 7, 2022

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

November 9, 2022

Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop

October 6, 2022

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

September 29, 2022

Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium

September 15, 2022

Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

September 11, 2022

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.

August 21, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 19 decks. Every deck is listed under its year.